Denver, CO (PRWEB) February 19, 2013
The medication resource center DrugRisk.com is alerting patients taking the blood thinner Pradaxa for atrial fibrillation that new information for the drug has been added to the site. Amid a new study warning of Pradaxa bleeding risks, reports show the number of patients filing legal claims for injury has increased.
“DrugRisk seeks to improve the safety of patients using popular drugs and medical devices by providing the latest warnings, recalls, studies and litigation news. With a drug like Pradaxa, this information can change monthly,“ explains DrugRisk representative Ryan Mayer.
The resource center contains information that shows experts still disagree about the safety of Pradaxa. The FDA recently issued an update that the drug carries the same risks as warfarin.* However, the American College of Cardiology has warned that Pradaxa use can significantly increase the risk of bleeding complications compared to warfarin.**
Now, DrugRisk has added new information from the Institute for Safe Medication Practices, which ranks anticoagulants like Pradaxa among the most dangerous of outpatient drugs. Also, in reviewing reports of bleeding submitted to the FDA, the Institute found that bleeding caused by Pradaxa is nearly 5 times as likely to result in death than with warfarin.***
In legal news, the resource center has learned that, due to the number of patients filing Pradaxa lawsuits for bleeding side effects, the cases are being sent to a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
In the latest update from the Judicial Panel on Multi-District Litigation, court officials indicated the number of Pradaxa lawsuits filed had grown by nearly 17% in recent mo
Copyright©2012 Vocus, Inc.
All rights reserved